Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riliprubart Long-term Extension Study in CIDP
NCT06859099Phase 3Enrolling by invitation
- Sponsor
- Sanofi
- Start
- Apr 2025
- Primary completion
- Oct 2029
- Modality
- IgG Antibodies
- Countries
- 24
01
Overview
Phase 3, open-label trial of riliprubart in chronic inflammatory demyelinating polyneuropathy (CIDP), sponsored by Sanofi. Primary endpoint: Adverse Events at 4 years. Started Apr 2025; status: enrolling by invitation.
02
Drugs
riliprubart
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NCT06859099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06859099.